Urologische Klinik und Poliklinik » Forschung » Publikationen 2018

Publikationen 2018

Risk factors for 30-day complications after cancer surgery in geriatric patients: a secondary analysis.
Acta Anaesthesiol Scand. 2018;62(4): 451-463
Scholtz K, Spies CD, Mörgeli R, Eckardt R, von Dossow V, Braun S, Sehouli J, Bahra M, Stief CG, Wernecke KD, Schmidt M, PERATECS Group , Weiß-Gerlach E, Al-Hashem A, Brinkmann F, Collette AM, Degel F, de Beukelaer F, Geue S, Hartmann K, Hennig S, Hoffmann I, Mohr O, Petrov G

Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres.
Acta Oncol. 2018;: 1-7
Stenman M, Staehler M, Szabados B, Sandström P, Laurell A, Lindskog M, Harmenberg U

Aktuelle Aspekte zur Pathogenese und Therapie des Benignen Prostata-Syndroms (BPS).
Aktuelle Urol. 2018;49(4): 289
Gratzke C

[Conservative treatment options for female incontinence].
Aktuelle Urol. 2018;49(1): 73-77
Kretschmer A, Bauer RM

[Therapeutic options for stress urinary incontinence following surgery for benign prostate enlargement].
Aktuelle Urol. 2018;49(4): 334-338
Kretschmer A, Gratzke C

[Novel minimally invasive treatment options for male lower urinary tract symptoms].
Aktuelle Urol. 2018;49(4): 339-345
Magistro G, Westhofen T, Stief C, Gratzke C

[Pharmacological treatment of BPS].
Aktuelle Urol. 2018;49(4): 328-333
Westhofen T, Magistro G, Stief C, Gratzke C

[The UroLift® system for treatment of the benign prostatic syndrome (BPS)].
Aktuelle Urol. 2018;49(6): 515-518
Westhofen T, Magistro G, Stief C, Gratzke C

Inhibition of smooth muscle contraction and ARF6 activity by the inhibitor for cytohesin GEFs, secinH3, in the human prostate.
Am J Physiol Renal Physiol. 2018;314(1): F47-F57
Herlemann A, Keller P, Schott M, Tamalunas A, Ciotkowska A, Rutz B, Wang Y, Yu Q, Waidelich R, Strittmatter F, Stief CG, Gratzke C, Hennenberg M

Is beta-endorphin significant in the control of the male sexual response?
Andrologia. 2018;: e13049
Ückert S, Becker AJ, Bannowsky A, Stief CG, Kuczyk MA

A new 2% testosterone gel formulation: a comparison with currently available topical preparations.
Andrology. 2018;
Arver S, Stief C, de la Rosette J, Jones TH, Neijber A, Carrara D

No Differences in Renal Function between Balanced 6% Hydroxyethyl Starch (130/0.4) and 5% Albumin for Volume Replacement Therapy in Patients Undergoing Cystectomy: A Randomized Controlled Trial.
Anesthesiology. 2018;128(1): 67-78
Kammerer T, Brettner F, Hilferink S, Hulde N, Klug F, Pagel J, Karl A, Crispin A, Hofmann-Kiefer K, Conzen P, Rehm M

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.
Ann Oncol. 2018;29(10): 2098-2104
Staehler M, Motzer RJ, George DJ, Pandha HS, Donskov F, Escudier B, Pantuck AJ, Patel A, DeAnnuntis L, Bhattacharyya H, Ramaswamy K, Zanotti G, Lin X, Lechuga M, Serfass L, Paty J, Ravaud A

Near-infrared autofluorescence imaging to detect parathyroid glands in thyroid surgery.
Ann R Coll Surg Engl. 2018;100(1): 33-36
Ladurner R, Al Arabi N, Guendogar U, Hallfeldt K, Stepp H, Gallwas J

Distress in patients with renal cell carcinoma: a curious gap in knowledge.
BJU Int. 2018;
Bergerot CD, Battle D, Staehler MD, Pal SK

How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.
BJU Int. 2018;122(5): 823-830
Gandaglia G, van den Bergh RCN, Tilki D, Fossati N, Ost P, Surcel CI, Sooriakumaran P, Tsaur I, Valerio M, Kretschmer A, Zaffuto E, Salomon L, Montorsi F, Graefen M, van der Poel H, de la Taille A, Briganti A, Ploussard G, The European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP)

Peri-operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score-weighted European multicentre study.
BJU Int. 2018;121(1): 101-110 
Vetterlein MW, Gild P, Kluth LA, Seisen T, Gierth M, Fritsche HM, Burger M, Protzel C, Hakenberg OW, von Landenberg N, Roghmann F, Noldus J, Nuhn P, Pycha A, Rink M, Chun FK, May M, Fisch M, Aziz A, PROMETRICS 2011 Study Group , Bartsch G, Bolenz C, Brookman-May S, Buchner A, Durschnabel M, Ellinger J, Froehner M, Georgieva G, Gilfrich C, Gördük M, Grimm MO, Hadaschik B, Haferkamp A, Hartmann F, Herrmann E, Hertle L, Hohenfellner M, Janetschek G, Keck B, Kraischits N, Krausse A, Lusuardi L, Martini T, Michel MS, Moritz R, Müller SC, Novotny V, Pahernik S, Palisaar RJ, Ponholzer A, Roigas J, Schmid M, Schramek P, Seitz C, Sikic D, Stief CG, Syring I, Traumann M, Vallo S, Wagenlehner FM, Weidner W, Wirth MP, Wullich B

A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial.
Blood Press Monit. 2018;23(3): 153-163
Weber MA, Chapple CR, Gratzke C, Herschorn S, Robinson D, Frankel JM, Ridder AM, Stoelzel M, Paireddy A, van Maanen R, White WB

Inhibition of human prostate smooth muscle contraction by the LIM kinase inhibitors, SR7826 and LIMKi3.
Br J Pharmacol. 2018;
Yu Q, Gratzke C, Wang Y, Herlemann A, Sterr CM, Rutz B, Ciotkowska A, Wang X, Strittmatter F, Stief CG, Hennenberg M

Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).
Cancer. 2018;124(5): 934-942
Siva S, Louie AV, Warner A, Muacevic A, Gandhidasan S, Ponsky L, Ellis R, Kaplan I, Mahadevan A, Chu W, Swaminath A, Onishi H, Teh B, Correa RJ, Lo SS, Staehler M

A second-derivate fitting algorithm for the quantification of free hemoglobin in human plasma.
Clin Biochem. 2018;56: 62-69
Paal M, Lang A, Hennig G, Buchholtz ML, Sroka R, Vogeser M

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.
Clin Cancer Res. 2018;
George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Escudier B, Gerletti P, Li S, Casy M, Laguerre B, Pandha H, Pantuck A, Patel A, Lechuga MJ, Ravaud A

Phase III Trial of Adjuvant Sunitinib in Patients With High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.
Clin Cancer Res. 2018;
George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Donskov F, Escudier B, Li S, Casey M, Valota O, Laguerre B, Pantuck AJ, Pandha H, Patel A, Lechuga MJ, Ravaud A

Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.
Clin Cancer Res. 2018;24(18): 4407-4415
Rini BI, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, Febbo PG, Li R, Lin X, Valota O, Staehler M, Motzer RJ, Ravaud A

Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry.
Clin Genitourin Cancer. 2018;
Goebell PJ, Staehler M, Müller L, Nusch A, Scheffler M, Sauer A, von Verschuer U, Tech S, Kruggel L, Jänicke M, Marschner N, RCC-Registry Group (Tumour Registry of Advanced Renal Cell Carcinoma)

Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
Clin Genitourin Cancer. 2018;
Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM

Surgical High-risk Patients With ASA >= 3 Undergoing Radical Cystectomy: Morbidity, Mortality, and Predictors for Major Complications in a High-volume Tertiary Center.
Clin Genitourin Cancer. 2018;
Schulz GB, Grimm T, Buchner A, Jokisch F, Kretschmer A, Casuscelli J, Ziegelmüller B, Stief CG, Karl A

Imaging in Suspected Renal-Cell Carcinoma: Systematic Review.
Clin Genitourin Cancer. 2018;
Vogel C, Ziegelmüller B, Ljungberg B, Bensalah K, Bex A, Canfield S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Albiges L, Stewart F, Volpe A, Graser A, Schlemmer M, Yuan C, Lam T, Staehler M

Contrast enhanced ultrasound (CEUS) with MRI image fusion for monitoring focal therapy of prostate cancer with high intensity focused ultrasound (HIFU)1.
Clin Hemorheol Microcirc. 2018;69(1-2): 93-100
Apfelbeck M, Clevert DA, Ricke J, Stief C, Schlenker B

MRI-TRUS fusion biopsy of the prostate: Quality of image fusion in a clinical setting.
Clin Hemorheol Microcirc. 2018;
Schlenker B, Apfelbeck M, Buchner A, Stief C, Clevert DA

Comparison of PIRADS 3 lesions with histopathological findings after MRI-fusion targeted biopsy of the prostate in a real world-setting.
Clin Hemorheol Microcirc. 2018;
Schlenker B, Apfelbeck M, Chaloupka M, Stief CG, Clevert DA

The new kids on the block: prostatic urethral lift (Urolift) and convective water vapor energy ablation (Rez?m).
Curr Opin Urol. 2018;
Magistro G, Weinhold P, Stief CG, Gratzke C

Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate.
Eur J Cancer. 2018;
Eze C, Manapov F, Gratzke C, Schmidt-Hegemann NS, Jung A, Kirchner T, Heinemann V, Stief CG, Belka C, Boeck S

Inhibition of prostatic smooth muscle contraction by the inhibitor of G protein-coupled receptor kinase 2/3, CMPD101.
Eur J Pharmacol. 2018;831: 9-19
Yu Q, Gratzke C, Wang Y, Herlemann A, Strittmatter F, Rutz B, Stief CG, Hennenberg M

Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma.
Eur Urol. 2018;74(6): 805-809
Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Abu-Ghanem Y, Staehler M, Volpe A, Powles T

A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use D
Eur Urol. 2018;74(6): 849-851
Bex A, Albiges L, Staehler M, Bensalah K, Giles RH, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Abu-Ghanem Y, Volpe A, Ljungberg B, Escudier B, Powles T

Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR).
Eur Urol. 2018;
Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A

New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?
Eur Urol. 2018;73(1): 1-3
Escudier B, Staehler M

Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
Eur Urol. 2018;74(4): 501-509
Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S, Rechberger T, Mueller ER

Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy.
Eur Urol. 2018;73(2): 215-223
Herlemann A, Cowan JE, Carroll PR, Cooperberg MR

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Eur Urol. 2018;73(1): 62-68
Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M

Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma.
Eur Urol. 2018;74(6): 842-843
Staehler M, Battle D, Bex A, Hammers H, George D

Delaying Surgical Treatment of Penile Fracture Results in Poor Functional Outcomes: Results from a Large Retrospective Multicenter European Study.
Eur Urol Focus. 2018;4(1): 106-110
Bozzini G, Albersen M, Otero JR, Margreiter M, Cruz EG, Mueller A, Gratzke C, Serefoglu EC, Salamanca JIM, Verze P, European Association of Urology Young Academic Urologists Men's Health working party

Latest Evidence on the Impact of Smoking, Sports, and Sexual Activity as Modifiable Lifestyle Risk Factors for Prostate Cancer Incidence, Recurrence, and Progression: A Systematic Review of the Literature by the European Association of Urology Section of Oncological Urology (ESOU)
Eur Urol Focus. 2018;
Brookman-May SD, Campi R, Henríquez JDS, Klatte T, Langenhuijsen JF, Brausi M, Linares-Espinós E, Volpe A, Marszalek M, Akdogan B, Roll C, Stief CG, Rodriguez-Faba O, Minervini A

Impact of Metabolic Diseases, Drugs, and Dietary Factors on Prostate Cancer Risk, Recurrence, and Survival: A Systematic Review by the European Association of Urology Section of Oncological Urology.
Eur Urol Focus. 2018;
Campi R, Brookman-May SD, Subiela Henríquez JD, Akdo?an B, Brausi M, Klatte T, Langenhuijsen JF, Linares-Espinos E, Marszalek M, Roupret M, Stief CG, Volpe A, Minervini A, Rodriguez-Faba O

Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis.
Eur Urol Focus. 2018;
Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A

Vaccine Development for Urinary Tract Infections: Where Do We Stand?
Eur Urol Focus. 2018;
Magistro G, Stief CG

Mini-Review: What Is New in Urolift?
Eur Urol Focus. 2018;
Magistro G, Stief CG, Woo HH

The Urinary Tract Microbiome: The Answer to All Our Open Questions?
Eur Urol Focus. 2018;
Magistro G, Stief CG

Urological Infections: "The Time for Change is Now".
Eur Urol Focus. 2018;
Magistro G

What's New in TIND?
Eur Urol Focus. 2018;4(1): 40-42
Marcon J, Magistro G, Stief CG, Grimm T

Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).
Eur Urol Focus. 2018;
Noweski A, Roosen A, Lebdai S, Barret E, Emberton M, Benzaghou F, Apfelbeck M, Gaillac B, Gratzke C, Stief C, Azzouzi AR

Clinical Trials in Benign Prostatic Hyperplasia: A Moving Target of Success.
Eur Urol Focus. 2018;
Thomas D, Chung C, Zhang Y, Te A, Gratzke C, Woo H, Chughtai B

The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis.
Eur Urol Focus. 2018;4(3): 369-375
Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Albersen M, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Van Der Poel H, Walz J, De Meerleer G, Bossi A, Haustermans K, Van Poppel H, Spahn M, Joniau S, European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT)

Inhibition of Prostate Smooth Muscle Contraction by Inhibitors of Polo-Like Kinases.
Front Physiol. 2018;9: 734
Hennenberg M, Kuppermann P, Yu Q, Herlemann A, Tamalunas A, Wang Y, Rutz B, Ciotkowska A, Strittmatter F, Stief CG, Gratzke C

High proliferation rate and TNM-stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma.
Hum Pathol. 2018;
Polifka I, Agaimy A, Herrmann E, Spath V, Trojan L, Stöckle M, Becker F, Ströbel P, Wülfing C, Schrader AJ, Barth P, Staehler M, Stief C, Hohenfellner M, Macher-Göppinger S, Höfler H, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Haferkamp A, Geppert CI, Stöhr C, Hartmann A, German Network Of Kidney Cancer

Local treatment for metastatic prostate cancer: A systematic review.
Int J Urol. 2018;25(5): 390-403
Tilki D, Pompe RS, Bandini M, Marchioni M, Kretschmer A, Tian Z, Karakiewicz PI, Evans CP

Rapid spectrophotometric quantification of urinary porphyrins and porphobilinogen as screening tool for attacks of acute porphyria.
J Biomed Opt. 2018;23(5): 1-12
Lang A, Heckl C, Vogeser M, Stauch T, Homann C, Hennig G, Sroka R, Stepp H

Ultrafast dynamics of hard tissue ablation using femtosecond-lasers.
J Biophotonics. 2018;: e201700373
Domke M, Wick S, Laible M, Rapp S, Huber HP, Sroka R

Photothermal therapy enhanced the effectiveness of imiquimod against refractory cutaneous warts through boosting immune responses.
J Biophotonics. 2018;: e201800149
Shi L, Luo M, Zhang F, Zhang L, Wang B, Liu P, Zhang Y, Zhang H, Yang D, Zhang G, Zhou F, Stepp H, Sroka R, Chen WR, Wang X

Cardiovascular Safety of the ? -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial.
J Clin Pharmacol. 2018;
White WB, Chapple C, Gratzke C, Herschorn S, Robinson D, Frankel J, Ridder A, Stoelzel M, Paireddy A, van Maanen R, Weber MA

A simple and highly efficient method for gene silencing in Escherichia coli.
J Microbiol Methods. 2018;154: 25-32
Magistro G, Magistro C, Stief CG, Schubert S

Impact of Ga-PSMA-PET/CT on the radiotherapeutic approach for prostate cancer in comparison to CT - a retrospective analysis.
J Nucl Med. 2018;
Schmidt-Hegemann NS, Chukwuka E, Minglun L, Rogowski P, Schaefer C, Stief C, Buchner A, Zamboglou C, Fendler WP, Ganswindt U, Cyran C, Bartenstein P, Belka C, Ilhan H

Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis.
J Nucl Med. 2018;
Schmidt-Hegemann NS, Stief C, Kim TH, Eze C, Kirste S, Strouthos I, Li M, Schultze-Seemann W, Ilhan H, Fendler WP, Bartenstein P, Grosu AL, Ganswindt U, Belka C, Meyer PT, Zamboglou C

ABCG2-mediated suppression of chlorin e6 accumulation and photodynamic therapy efficiency in glioblastoma cell lines can be reversed by KO143.
J Photochem Photobiol B. 2018;178: 182-191
Abdel Gaber SA, Müller P, Zimmermann W, Hüttenberger D, Wittig R, Abdel Kader MH, Stepp H

A prospective randomised comparison between the transperitoneal and retroperitoneoscopic approaches for robotic-assisted pyeloplasty in a single surgeon, single centre study.
J Robot Surg. 2018;12(1): 131-137
Khoder WY, Waidelich R, Ghamdi AMA, Schulz T, Becker A, Stief CG

Validation of a High-End Virtual Reality Simulator for Training Transurethral Resection of Bladder Tumors.
J Surg Educ. 2018;
Schulz GB, Grimm T, Buchner A, Jokisch F, Casuscelli J, Kretschmer A, Mumm JN, Ziegelmüller B, Stief CG, Karl A

Enhanced Recovery after Surgery Protocol for Pediatric Urological Augmentation and Diversion Surgery Using Small Bowel.
J Urol. 2018;200(5): 1100-1106
Haid B, Karl A, Koen M, Mottl W, Haid A, Oswald J

In vitro investigations of propulsion during laser lithotripsy using video tracking.
Lasers Surg Med. 2018;50(4): 333-339
Eisel M, Ströbl S, Pongratz T, Strittmatter F, Sroka R

Laser-assisted fixation of a nitinol stapes prosthesis.
Lasers Surg Med. 2018;50(2): 153-157
Schrötzlmair F, Suchan F, Pongratz T, Krause E, Müller J, Sroka R

5-ALA in the management of malignant glioma.
Lasers Surg Med. 2018;50(5): 399-419
Stepp H, Stummer W

[Burning sensation during urination].
MMW Fortschr Med. 2018;160(20): 52-55
Magistro G, Marcon J, Schulz GB, Bischoff R, Stief CG

MMW Fortschr Med. 2018;160(4): 44
Marcon J, Stief CG, Becker A

Harnblasenkarzinom: Update für den Hausarzt.
MMW Fortschr Med. 2018;160(21-22): 42-43
Stief C

[Undescended testis: current pathways of diagnostics and treatment].
MMW Fortschr Med. 2018;160(12): 58-61
Stredele R, Apfelbeck M, Mainusch M, Lellig K, Karl A, Tritschler S, Stief C, Riccabona M

[Urology - what are the most important trends over the last decade?]
MMW Fortschr Med. 2018;160(Suppl 3): 99-102
Strittmatter F, Gratzke C, Stief C

Contribution of yersiniabactin to the virulence of an Escherichia coli sequence type 69 ("clonal group A") cystitis isolate in murine models of urinary tract infection and sepsis.
Microb Pathog. 2018;120: 128-131
Johnson JR, Magistro G, Clabots C, Porter S, Manges A, Thuras P, Schubert S

Improved prediction of nephron-sparing surgery versus radical nephrectomy by the optimized R.E.N.A.L. (optR.E.N.A.L.) score in patients undergoing surgery for renal masses.
Minerva Urol Nefrol. 2018;
Sterzik A, Solyanik O, Eichelberg C, Jost M, Graser A, Lausenmeyer EM, Otto W, Waidelich R, Stief CG, Burger M, May M, Brookman-May SD

An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma.
Nat Rev Urol. 2018;15(8): 511-521
Grünwald V, Eberhardt B, Bex A, Flörcken A, Gauler T, Derlin T, Panzica M, Dürr HR, Grötz KA, Giles RH, von Falck C, Graser A, Muacevic A, Staehler M

Long-term functional outcome analysis in a large cohort of patients after radical prostatectomy.
Neurourol Urodyn. 2018;
Grabbert M, Buchner A, Butler-Ransohoff C, Kretschmer A, Stief CG, Bauer RM

Adreno-muscarinic synergy in the male human urinary outflow tract.
Neurourol Urodyn. 2018;
Walther S, Strittmatter F, Hennenberg M, Gratzke C, Stief CG, Roosen A

Transient receptor potential a1 (TRPA1) agonists inhibit contractions of the isolated human ureter.
Neurourol Urodyn. 2018;37(2): 600-608
Weinhold P, Hennenberg M, Strittmatter F, Stief CG, Gratzke C, Hedlund P

[Neuroendocrine prostate cancer].
Pathologe. 2018;39(4): 333-343
Tritschler S, Erdelkamp R, Stief C, Hentrich M

Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study.
Prostate Cancer Prostatic Dis. 2018;
Govers TM, Hessels D, Vlaeminck-Guillem V, Schmitz-Dräger BJ, Stief CG, Martinez-Ballesteros C, Ferro M, Borque-Fernando A, Rubio-Briones J, Sedelaar JPM, van Criekinge W, Schalken JA

Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.
Radiat Oncol. 2018;13(1): 37
Schmidt-Hegemann NS, Fendler WP, Ilhan H, Herlemann A, Buchner A, Stief C, Eze C, Rogowski P, Li M, Bartenstein P, Ganswindt U, Belka C

[CEUS-Use in testicular pathologies].
Radiologe. 2018;58(6): 572-578
Marcon J, Trottmann M, Stief CG, Clevert DA

Tissue Phenomics for prognostic biomarker discovery in low- and intermediate-risk prostate cancer.
Sci Rep. 2018;8(1): 4470
Harder N, Athelogou M, Hessel H, Brieu N, Yigitsoy M, Zimmermann J, Baatz M, Buchner A, Stief CG, Kirchner T, Binnig G, Schmidt G, Huss R

Contrast-Enhanced Ultrasonography (CEUS) Reveals Active Bleeding into the Urinary Bladder in a Patient with Bladder Tamponade.
Ultraschall Med. 2018;39(4): 454-456
Nörenberg D, Mueller-Peltzer K, Tritschler S, Reiser M, Clevert DA

The TiLOOP® Male Sling: Did We Forejudge.
Urol Int. 2018;100(2): 216-221
Hüsch T, Kretschmer A, Thomsen F, Kronlachner D, Kurosch M, Obaje A, Anding R, Kirschner-Hermanns R, Pottek T, Rose A, Olianas R, Friedl A, Hübner W, Homberg R, Pfitzenmaier J, Grein U, Queissert F, Naumann CM, Schweiger J, Wotzka C, Nyarangi-Dix J, Brehmer B, Ulm K, Bauer RM, Haferkamp A, Debates On Male Incontinence (DOMINO)-Project 8

Cystic Appearance on Imaging Methods (Bosniak III-IV) in Histologically Confirmed Papillary Renal Cell Carcinoma is Mainly Characteristic of Papillary Renal Cell Carcinoma Type 1 and Might Predict a Relatively Indolent Behavior of Papillary Renal Cell Car
Urol Int. 2018;101(4): 409-416
Procházková K, Mírka H, Trávní?ek I, Pitra T, Kolár J, Rou?arová M, Ho?ek P, Bajcurová K, Ferda J, Staehler M, Brookman May SD, Hes O, Hora M

[Bulbar urethral strictures : A trivial urological disease or a surgical challenge?]
Urologe A. 2018;57(1): 17-20
Austen M, Breul J, Tritschler S

[Stricture of the vesicourethral anastomosis after radical prostatectomy].
Urologe A. 2018;57(1): 29-33
Beck V, Apfelbeck M, Chaloupka M, Kretschmer A, Strittmatter F, Tritschler S

[Diagnostic workup of urethral strictures].
Urologe A. 2018;57(1): 6-10
Chaloupka M, Beck V, Kretschmer A, Tritschler S, Stief CG, Strittmatter F

[Radical cystectomy and urinary diversion-what is important ?]
Urologe A. 2018;57(6): 673-678
Noldus J, Niegisch G, Pycha A, Karl A

[Bladder cancer : Current diagnosis and treatment modalities].
Urologe A. 2018;57(6): 655-656
Retz M, Karl A

[Urethral strictures : From diagnostic workup to appropriate and situation-dependent treatment].
Urologe A. 2018;57(1): 4-5
Strittmatter F, Stief CG

[En bloc resection and vaporization techniques for the treatment of bladder cancer].
Urologe A. 2018;57(6): 665-672
Struck JP, Karl A, Schwentner C, Herrmann TRW, Kramer MW

[Epidemiology and diagnostic assessment of small renal masses].
Urologe A. 2018;
Ziegelmüller BK, Spek A, Szabados B, Casuscelli J, Clevert DA, Staehler M

Emphysematous pyelonephritis: Case report and literature overview.
Urologia. 2018;85(3): 123-126
Ziegelmüller BK, Szabados B, Spek A, Casuscelli J, Stief C, Staehler M

Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications.
Virchows Arch. 2018;472(5): 749-758
Barth I, Schneider U, Grimm T, Karl A, Horst D, Gaisa NT, Knüchel R, Garczyk S

The increase of stage, grading, and metastases in patients undergoing radical prostatectomy during the last decade.
World J Urol. 2018;
Beck V, Schlenker B, Herlemann A, Apfelbeck M, Buchner A, Gratzke C, Stief CG, Tritschler S

Imaging modalities in synchronous oligometastatic prostate cancer.
World J Urol. 2018;
Futterer JJ, Surcel C, van den Bergh R, Borgmann H, Briganti A, Gandaglia G, Kretschmer A, Ost P, Sooriakumaran P, Tilki D, Valerio M, Ploussard G, De Visschere PJL, Tsaur I, EAU-YAU Prostate Cancer Working Party

The AdVance and AdVanceXP male sling in urinary incontinence: is there a difference?
World J Urol. 2018;36(10): 1657-1662
Hüsch T, Kretschmer A, Thomsen F, Kronlachner D, Kurosch M, Obaje A, Anding R, Kirschner-Hermanns R, Pottek T, Rose A, Olianas R, Lusuardi L, Friedl A, Homberg R, Pfitzenmaier J, Queissert F, Naumann CM, Schweiger J, Wotzka C, Nyarangi-Dix J, Brehmer B, Abdunnur R, Loertzer H, Ulm K, Hübner W, Bauer RM, Haferkamp A

External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
World J Urol. 2018;
Marconi L, de Bruijn R, van Werkhoven E, Beisland C, Fife K, Heidenreich A, Kapoor A, Karam J, Kauffmann C, Klatte T, Ljungberg B, Matin S, Sjoberg D, Staehler M, Stewart GD, Tanguay S, Uzzo R, Welsh S, Wood L, Wood C, Bex A

Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?
World J Urol. 2018;
Ploussard G, Borgmann H, Briganti A, de Visschere P, Fütterer JJ, Gandaglia G, Heidegger I, Kretschmer A, Mathieu R, Ost P, Sooriakumaran P, Surcel C, Tilki D, Tsaur I, Valerio M, van den Bergh R, EAU-YAU Prostate Cancer Working Group

Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years.
World J Urol. 2018;
Sievert KD, Schonthaler M, Berges R, Toomey P, Drager D, Herlemann A, Miller F, Wetterauer U, Volkmer B, Gratzke C, Amend B

Induction of porcine-specific regulatory T cells with high specificity and expression of IL-10 and TGF-?1 using baboon-derived tolerogenic dendritic cells.
Xenotransplantation. 2018;25(1)
Li M, Eckl J, Abicht JM, Mayr T, Reichart B, Schendel DJ, Pohla H